Universal reference book for medicines
Name of the drug: OMNISCAN

Active substance: gadodiamide

Type: Contrast diagnostic drug for magnetic resonance imaging

Manufacturer: GE HEALTHCARE IRELAND (Ireland)
Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..

Contrast diagnostic paramagnetic non-ionic agent.
Due to its paramagnetic properties, it enhances the contrast of the image during MRI and facilitates the visualization of abnormal structures or formations in the body, incl. in the central nervous system. It causes a signal increase in those areas where there is a violation of the function of the BBB due to its damage in the pathological process.
After iv introduction gadodiamid quickly distributed in the extracellular fluid.
V d is equivalent to the volume of extracellular fluid. The half-life period is approximately 4 minutes. Binding to proteins is not revealed.
Does not penetrate intact GEB.

T 1/2 is about 70 minutes.
It is almost completely excreted by the kidneys in the unmodified form by glomerular filtration. Four hours after intravenous injection in urine, 85% of the active substance is detected, after 24 hours it is 95-98%.
For contrast enhancement with MRI of the head, spinal canal, whole body.

With IV introduction to adults and children older than 2 years with a body weight of up to 100 kg, a single dose is 0.1 mmol / kg;
with a body weight of more than 100 kg, a single dose is 10 mmol.
From the side of the central nervous system: rarely - dizziness, headache, change in taste and smell;
in isolated cases - drowsiness.
From the digestive system: rarely - nausea;
in isolated cases - drowsiness.
Allergic reactions: rarely - urticaria, skin itching, choking in the throat.

Other: a feeling of warmth or cooling in the whole body is possible.

Local reactions: local soreness, a feeling of pressure at the injection site are possible.

Renal insufficiency, hypersensitivity to gadodiomide.

Application in pregnancy is possible only in cases of extreme necessity.
During lactation - breast-feeding should be stopped at least 24 hours before the introduction of gadodiamide and resume no earlier than 24 hours after its introduction.
In experimental studies on rodents, it was shown that gadodiamide does not affect fertility and does not have a teratogenic effect.

Contraindicated in renal failure.
Do not use in patients with impaired renal function at a glomerular filtration rate of less than 30 ml / min.
Clinical data on the use of gadodiamide in children under 2 years are limited.

Do not use in patients with impaired renal function at a glomerular filtration rate of less than 30 ml / min.

Gadodiamide should be administered under conditions that allow, if necessary, immediate intensive care.

Clinical data on the use of gadodiamide in children under 2 years are limited.

Gadodiamid distorts the results of measuring the concentration of calcium in the blood plasma, which are carried out colorimetrically, as well as the results of the determination of certain electrolytes (including iron).
Therefore, these studies should not be conducted within 12-24 hours after the administration of the gadodiamide.
Clinically significant interaction of gadodiamide with other drugs has not been established.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!